Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, has issued a shareholder letter and corporate update outlining its developments and initiatives for 2020 and anticipated milestones for 2021 and beyond. “We achieved many significant milestones in 2020 that have set the stage for a transformational 2021,” stated Rodney Varner, president and CEO of Genprex. “The primary focus this past year was on the preparation for our two lead clinical trials in non-small cell lung cancer (‘NSCLC’). Our Acclaim-1 clinical trial will combine REQORSA with Tagrisso(R) for patients with late stage NSCLC whose disease progressed after treatment with Tagrisso. Our Acclaim-2 clinical trial will combine REQORSA with Keytruda(R) for NSCLC patients who are low expressors (1% to 49%) of the protein programmed death-ligand 1 (‘PD-L1’). We remain on track to initiate both trials in the first-half of 2021. Additionally, the $40 million-plus in capital infusions in 2020 provided us with a strong balance sheet as 2021 begins. We are grateful for the confidence and support of our shareholders and look forward to executing on our strategies to achieve a number of potentially value-creating milestones.”
To view the full press release, visit https://ibn.fm/zvam2
About Genprex Inc.
Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.